Wang Wesley Wei, Zeng Yu, Wu Bo, Deiters Alexander, Liu Wenshe R
Department of Chemistry, Texas A&M University , College Station, Texas 77843-3255, United States.
Department of Chemistry, University of Pittsburgh , Pittsburgh, Pennsylvania 15260, United States.
ACS Chem Biol. 2016 Jul 15;11(7):1973-81. doi: 10.1021/acschembio.6b00243. Epub 2016 May 17.
As a member of a highly conserved family of NAD(+)-dependent histone deacetylases, Sirt6 is a key regulator of mammalian genome stability, metabolism, and life span. Previous studies indicated that Sirt6 is hardwired to remove histone acetylation at H3K9 and H3K56. However, how Sirt6 recognizes its nucleosome substrates has been elusive due to the difficulty of accessing homogeneous acetyl-nucleosomes and the low activity of Sirt6 toward peptide substrates. Based on the fact that Sirt6 has an enhanced activity to remove long chain fatty acylation from lysine, we developed an approach to recombinantly synthesize histone H3 with a fatty acylated lysine, N(ε)-(7-octenoyl)-lysine (OcK), installed at a number of lysine sites and used these acyl-H3 proteins to assemble acyl-nucleosomes as active Sirt6 substrates. A chemical biology approach that visualizes OcK in nucleosomes and therefore allows direct sensitization of Sirt6 activities on its acyl-nucleosome substrates was also formulated. By combining these two approaches, we showed that Sirt6 actively removes acylation from H3K9, H3K18, and H3K27; has relatively low activities toward H3K4 and K3K23; but sluggishly removes acylation at H3K14, H3K36, H3K56, and H3K79. Overexpressing Sirt6 in 293T cells led to downregulated acetylation at H3K18 and K3K27, confirming these two novel Sirt6-targeted nucleosome lysine sites in cells. Given that downregulation of H3K18 acetylation is correlated with a poor prognosis of several cancer types and H3K27 acetylation antagonizes repressive gene regulation by di- and trimethylation at H3K27, our current study implies that Sirt6 may serve as a target for cancer intervention and regulatory pathway investigation in cells.
作为NAD⁺依赖性组蛋白去乙酰化酶高度保守家族的成员,Sirt6是哺乳动物基因组稳定性、代谢和寿命的关键调节因子。先前的研究表明,Sirt6可特异性去除H3K9和H3K56处的组蛋白乙酰化修饰。然而,由于难以获得均一的乙酰化核小体以及Sirt6对肽底物的活性较低,Sirt6如何识别其核小体底物一直难以捉摸。基于Sirt6具有增强的从赖氨酸上去除长链脂肪酰化修饰的活性这一事实,我们开发了一种方法,通过重组合成在多个赖氨酸位点安装了脂肪酰化赖氨酸N(ε)-(7-辛烯酰基)-赖氨酸(OcK)的组蛋白H3,并使用这些酰基-H3蛋白组装酰基核小体作为活性Sirt6底物。我们还制定了一种化学生物学方法,该方法可在核小体中可视化OcK,从而直接检测Sirt6对其酰基核小体底物的活性。通过结合这两种方法,我们发现Sirt6可有效去除H3K9、H3K18和H3K27上的酰化修饰;对H3K4和K3K23的活性相对较低;但对H3K14、H3K36、H3K56和H3K79上的酰化修饰去除缓慢。在293T细胞中过表达Sirt6导致H3K18和K3K27的乙酰化水平下调,证实了细胞中这两个新的Sirt6靶向核小体赖氨酸位点。鉴于H3K18乙酰化水平的下调与几种癌症类型的不良预后相关,并且H3K27乙酰化拮抗H3K27二甲基化和三甲基化的抑制性基因调控,我们目前的研究表明,Sirt6可能作为癌症干预和细胞中调控途径研究的靶点。